430 related articles for article (PubMed ID: 9049244)
21. Topoisomerase II is a structural component of mitotic chromosome scaffolds.
Earnshaw WC; Halligan B; Cooke CA; Heck MM; Liu LF
J Cell Biol; 1985 May; 100(5):1706-15. PubMed ID: 2985625
[TBL] [Abstract][Full Text] [Related]
22. Dynamics of tobacco DNA topoisomerases II in cell cycle regulation: to manage topological constrains during replication, transcription and mitotic chromosome condensation and segregation.
Singh BN; Achary VMM; Panditi V; Sopory SK; Reddy MK
Plant Mol Biol; 2017 Aug; 94(6):595-607. PubMed ID: 28634865
[TBL] [Abstract][Full Text] [Related]
23. Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and IIalpha.
Syrovets T; Büchele B; Gedig E; Slupsky JR; Simmet T
Mol Pharmacol; 2000 Jul; 58(1):71-81. PubMed ID: 10860928
[TBL] [Abstract][Full Text] [Related]
24. The α isoform of topoisomerase II is required for hypercompaction of mitotic chromosomes in human cells.
Farr CJ; Antoniou-Kourounioti M; Mimmack ML; Volkov A; Porter AC
Nucleic Acids Res; 2014 Apr; 42(7):4414-26. PubMed ID: 24476913
[TBL] [Abstract][Full Text] [Related]
25. Down-regulation of DNA topoisomerase IIalpha leads to prolonged cell cycle transit in G2 and early M phases and increased survival to microtubule-interacting agents.
Skladanowski A; Côme MG; Sabisz M; Escargueil AE; Larsen AK
Mol Pharmacol; 2005 Sep; 68(3):625-34. PubMed ID: 15942022
[TBL] [Abstract][Full Text] [Related]
26. Subnuclear distribution of DNA topoisomerase I and Bax protein in normal and xeroderma pigmentosum fibroblasts after irradiation with UV light and gamma rays or treatment with topotecan.
Thielmann HW; Popanda O; Staab HJ
J Cancer Res Clin Oncol; 1999; 125(3-4):193-208. PubMed ID: 10235474
[TBL] [Abstract][Full Text] [Related]
27. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line.
Son YS; Suh JM; Ahn SH; Kim JC; Yi JY; Hur KC; Hong WS; Muller MT; Chung IK
Cancer Chemother Pharmacol; 1998; 41(5):353-60. PubMed ID: 9523730
[TBL] [Abstract][Full Text] [Related]
28. Expression of DNA topoisomerases in chronic proliferative kidney disease.
Ivanova LV; Rudolph P; Kellner U; Jürgensen A; Tareeva IE; Alm P; Proppe D
Kidney Int; 2000 Oct; 58(4):1603-12. PubMed ID: 11012894
[TBL] [Abstract][Full Text] [Related]
29. Both alpha and beta isoforms of mammalian DNA topoisomerase II associate with chromosomes in mitosis.
Null AP; Hudson J; Gorbsky GJ
Cell Growth Differ; 2002 Jul; 13(7):325-33. PubMed ID: 12133901
[TBL] [Abstract][Full Text] [Related]
30. Cellular distribution of mammalian DNA topoisomerase II is determined by its catalytically dispensable C-terminal domain.
Adachi N; Miyaike M; Kato S; Kanamaru R; Koyama H; Kikuchi A
Nucleic Acids Res; 1997 Aug; 25(15):3135-42. PubMed ID: 9224616
[TBL] [Abstract][Full Text] [Related]
31. TDP1 overexpression in human cells counteracts DNA damage mediated by topoisomerases I and II.
Barthelmes HU; Habermeyer M; Christensen MO; Mielke C; Interthal H; Pouliot JJ; Boege F; Marko D
J Biol Chem; 2004 Dec; 279(53):55618-25. PubMed ID: 15494395
[TBL] [Abstract][Full Text] [Related]
32. Fbxo28 promotes mitotic progression and regulates topoisomerase IIα-dependent DNA decatenation.
Kratz AS; Richter KT; Schlosser YT; Schmitt M; Shumilov A; Delecluse HJ; Hoffmann I
Cell Cycle; 2016 Dec; 15(24):3419-3431. PubMed ID: 27754753
[TBL] [Abstract][Full Text] [Related]
33. Altered expression and activity of topoisomerases during all-trans retinoic acid-induced differentiation of HL-60 cells.
Aoyama M; Grabowski DR; Isaacs RJ; Krivacic KA; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
Blood; 1998 Oct; 92(8):2863-70. PubMed ID: 9763571
[TBL] [Abstract][Full Text] [Related]
34. Polyamine-containing etoposide derivatives as poisons of human type II topoisomerases: Differential effects on topoisomerase IIα and IIβ.
Oviatt AA; Kuriappan JA; Minniti E; Vann KR; Onuorah P; Minarini A; De Vivo M; Osheroff N
Bioorg Med Chem Lett; 2018 Sep; 28(17):2961-2968. PubMed ID: 30006062
[TBL] [Abstract][Full Text] [Related]
35. The p53 tumor suppressor stimulates the catalytic activity of human topoisomerase IIalpha by enhancing the rate of ATP hydrolysis.
Kwon Y; Shin BS; Chung IK
J Biol Chem; 2000 Jun; 275(24):18503-10. PubMed ID: 10764786
[TBL] [Abstract][Full Text] [Related]
36. Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.
Kozuki T; Chikamori K; Surleac MD; Micluta MA; Petrescu AJ; Norris EJ; Elson P; Hoeltge GA; Grabowski DR; Porter ACG; Ganapathi RN; Ganapathi MK
Nucleic Acids Res; 2017 Jun; 45(10):5995-6010. PubMed ID: 28472494
[TBL] [Abstract][Full Text] [Related]
37. Effects of wild-type p53 expression on the quantity and activity of topoisomerase IIalpha and beta in various human cancer cell lines.
Hochhauser D; Valkov NI; Gump JL; Wei I; O'Hare C; Hartley J; Fan J; Bertino JR; Banerjee D; Sullivan DM
J Cell Biochem; 1999 Nov; 75(2):245-57. PubMed ID: 10502297
[TBL] [Abstract][Full Text] [Related]
38. Functional compatibility between isoform alpha and beta of type II DNA topoisomerase.
Sakaguchi A; Kikuchi A
J Cell Sci; 2004 Mar; 117(Pt 7):1047-54. PubMed ID: 14996935
[TBL] [Abstract][Full Text] [Related]
39. Expression of DNA topoisomerase I, IIalpha, and IIbeta in human brain tumors.
Morisaki K; Kuroda S; Matsumoto Y; Kunishio K; Nagao S
Brain Tumor Pathol; 2000; 17(1):7-13. PubMed ID: 10982004
[TBL] [Abstract][Full Text] [Related]
40. Anthocyanidins modulate the activity of human DNA topoisomerases I and II and affect cellular DNA integrity.
Habermeyer M; Fritz J; Barthelmes HU; Christensen MO; Larsen MK; Boege F; Marko D
Chem Res Toxicol; 2005 Sep; 18(9):1395-404. PubMed ID: 16167831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
